Lexicon Pharmaceuticals | LXRX - Ordinary Share Capital


Lexicon Pharmaceuticals reported $363.47M in Ordinary Share Capital for its fiscal quarter ending in December of 2025.





Ordinary Share Capital Change Date
Abbott USD 1.74B 2.94M Mar/2026
Acadia Pharmaceuticals USD 171.09M 1.9M Mar/2026
Agios Pharmaceuticals USD 59.34M 892K Mar/2026
Akebia Therapeutics USD 265.42M 199K Dec/2025
Alnylam Pharmaceuticals USD 133.73M 290K Jun/2026
AstraZeneca USD 1.55B 44K Jun/2026
BioMarin Pharmaceutical USD 193.54M 267K Jun/2026
Coherus Biosciences USD 121.16M 4.92M Dec/2025
Eli Lilly USD 943.5M 3.33M Mar/2026
Halozyme Therapeutics USD 114.04M 4.48M Jun/2026
Illumina USD 151.3M 607K Jun/2026
Insmed USD 218.28M 1.76M Jun/2026
Ironwood Pharmaceuticals USD 160K 0 Dec/2024
J&J USD 2.41B 1.35M Mar/2026
Lexicon Pharmaceuticals USD 363.47M 67K Dec/2025
MacroGenics USD 63.56M 241K Mar/2026
MannKind USD 309.91M 1M Jun/2026
Merck USD 2.47B 4.93M Mar/2026
Moderna USD 391M 2M Sep/2025
Novartis USD 1.9B 7.38M Jun/2026
PTC Therapeutics USD 82.88M 1.41M Mar/2026
Puma Biotechnology USD 5K 0 Jun/2024
Sarepta Therapeutics USD 105.62M 53K Jun/2026
Thermo Fisher Scientific USD 371.62M 1000 Jun/2026
Ultragenyx Pharmaceutical USD 98.3M 1.7M Mar/2026
United Therapeutics USD 42.68M 521K Jun/2026
Vanda Pharmaceuticals USD 58K 0 Dec/2024